AR062207A1 - Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer. - Google Patents

Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer.

Info

Publication number
AR062207A1
AR062207A1 ARP070103435A ARP070103435A AR062207A1 AR 062207 A1 AR062207 A1 AR 062207A1 AR P070103435 A ARP070103435 A AR P070103435A AR P070103435 A ARP070103435 A AR P070103435A AR 062207 A1 AR062207 A1 AR 062207A1
Authority
AR
Argentina
Prior art keywords
pyridazin
imidazo
benzamide
substituent
hydrogen atom
Prior art date
Application number
ARP070103435A
Other languages
English (en)
Inventor
Sakai Nozomu
Imamura Shinichi
Miyamoto Naoki
Hirayama Takaharu
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR062207A1 publication Critical patent/AR062207A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Un agente farmacéutico que contiene el compuesto que es un inhibidor de quinasa (VEGFR, VEGFR2, PDGFR, Raf), un inhibidor de angiogénesis, un agente para la prevencion o el tratamiento del cáncer, un inhibidor del crecimiento del cáncer o un supresor de la metástasis cancerosa. Reivindicacion 1: Un compuesto caracterizado por la formula (1) en donde anillo Y es un grupo cíclico opcionalmente sustituido; X es -O-, -S-, -S(O)-, -S(O)2- o -NR- (en donde R es un átomo de hidrogeno o un sustituyente); R1 es un átomo de hidrogeno o un sustituyente; R2 es un átomo de hidrogeno o un sustituyente; R3 es un átomo de hidrogeno o un sustituyente; R4 es un átomo de hidrogeno o un sustituyente; con la condicion de que cuando R1 es distinto de un amino opcionalmente sustituido, anillo Y sea un grupo cíclico sustituido con un amino opcionalmente sustituido, en donde el grupo cíclico también está opcionalmente sustituido, y que se excluyan [6-(feniltio)imidazo(1,2-b]piridazin-2- il]carbamato de metilo, [6-(fenilsulfinil)imidazo[1,2-b]piridazin-2-il]carbamato de metilo, 6-(4-acetamidofenoxi) imidazo[1,2-b]piridazin-2-carboxilato de etilo, 6-[4-(4-acetilpiperazin-1-il)fenoxi]imidazo[1,2- b]piridazin-2-carboxilato de etilo, N- [1-(imidazo[1,2-b]piridazin-6-ilamino)-2,5-dioxo- 1,2, 5, 6,7, 8-hexahidroquinolin-3-il]benzamida, N-[1-(imidazo[1,2-b]piridazin-6-ilamino)-7,7-dimetil-2,5- dioxo-1,2,5,6,7,8-hexahidroquinolin-3-il]benzamida, N-[1-(imidazo[1,2-b]piridazin-6-ilamino)- 2,5-dioxo-2,5,6,7- tetrahidro-1H-ciclopenta[b]piridin-3-il]benzamida, N-[1-(imidazo[1,2-b]piridazin-6-ilamino)-7-metil-2,5-dioxo- 1,2,5,6,7,8-hexahidroquinolin-3-il]benzamida, N-[(5E)-5-(imidazo[1,2-b]piridazin-6-ilhidrazono)-7-metil-2-oxo-4a,5, 6,7,8,8a-hexahidro-2H-cromen-3-il)benzamida, (6R, 7R)-3- (imidazo[1,2-b]piridazin-6-iltio)-8-oxo-7-[(fenilacetil)amino]-5-tia-1-azabiciclo[4,2,0]oct-2-en-2-carboxilato de 4-metoxibencilo, 4-[(3-metoxi-2-fenilimidazo[1,2-b)piridazin-6-il)tio]-N,N- dimetilanilina, 3-metoxi-6-(3-nitrofenoxi)-2-fenilimidazo[1,2-b]piridazina, 3-[(3-metoxi-2-fenilimidazo[1,2-b]piridazin-6-il)oxi)anilina, y 3-[(3-metoxi-2-fenilimidazo[1,2-b]piridazin-6-il)oxi]-N,N-dimetilanilina, o una de sus sales.
ARP070103435A 2006-08-04 2007-08-03 Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer. AR062207A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006213981 2006-08-04
JP2006331230 2006-12-07
JP2007144072 2007-05-30

Publications (1)

Publication Number Publication Date
AR062207A1 true AR062207A1 (es) 2008-10-22

Family

ID=38996616

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103435A AR062207A1 (es) 2006-08-04 2007-08-03 Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer.

Country Status (18)

Country Link
US (4) US8044049B2 (es)
EP (1) EP2049541B1 (es)
JP (1) JP5238697B2 (es)
KR (1) KR20090047509A (es)
AR (1) AR062207A1 (es)
AU (1) AU2007279595A1 (es)
BR (1) BRPI0714665A2 (es)
CA (1) CA2659971A1 (es)
CL (1) CL2007002261A1 (es)
CO (1) CO6150183A2 (es)
CR (1) CR10607A (es)
IL (1) IL196799A0 (es)
MA (1) MA30651B1 (es)
MX (1) MX2009001349A (es)
NO (1) NO20090986L (es)
PE (1) PE20080538A1 (es)
TW (1) TW200817409A (es)
WO (1) WO2008016192A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
US8431608B2 (en) * 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
CA2696631A1 (en) * 2007-08-17 2009-02-26 Icagen, Inc. Heterocycles as potassium channel modulators
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8389527B2 (en) 2008-02-06 2013-03-05 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
EA201001365A1 (ru) 2008-02-28 2011-04-29 Новартис Аг ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДУЕМОГО C-МЕТ ТИРОЗИНКИНАЗОЙ
CN101372475B (zh) * 2008-03-19 2012-01-04 南京工业大学 芳杂环取代的二苯脲类衍生物及其用途
EP2277881A4 (en) 2008-04-18 2011-09-07 Shionogi & Co HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
US8445509B2 (en) * 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
WO2010007099A1 (en) * 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
ES2461496T3 (es) 2008-10-02 2014-05-20 Respivert Limited Inhibidores de cinasa MAP p38
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
KR101784798B1 (ko) 2008-10-22 2017-10-16 어레이 바이오파마 인크. ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
JP5579619B2 (ja) * 2008-12-01 2014-08-27 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
CN102333770B (zh) 2008-12-11 2015-01-28 瑞斯比维特有限公司 P38map激酶抑制剂
CN102264705A (zh) 2008-12-24 2011-11-30 辛根塔有限公司 制备芳基酰胺的方法
KR20110113755A (ko) 2009-02-10 2011-10-18 아스트라제네카 아베 트리아졸로 〔4,3-ｂ〕 피리다진 유도체 및 전립샘암에 대한 이의 용도
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
US9145419B2 (en) 2010-04-28 2015-09-29 Bristol-Myers Squibb Company Imidazopyridazinyl compounds
CA2831935A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
RU2586333C1 (ru) 2011-12-09 2016-06-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные 4-гидрокси-1,2,3,4-тетрагидронафталин-1-ил-мочевины и их применение в лечении, среди прочего, заболеваний дыхательного тракта
EP2992112B1 (en) 2013-04-22 2020-06-03 Icahn School of Medicine at Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
US9988386B2 (en) 2013-05-30 2018-06-05 Kata Pharmaceuticals, Inc. Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof
EP3077393A1 (en) * 2013-12-06 2016-10-12 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN106068252B (zh) 2013-12-13 2023-02-03 欧洲化学农业有限公司 含硝化抑制剂的肥料混合物
WO2016086026A1 (en) * 2014-11-26 2016-06-02 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof
EP3231427A4 (en) * 2014-12-10 2018-07-11 Senju Pharmaceutical Co., Ltd. Aqueous liquid agent
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
CR20180501A (es) 2016-04-04 2019-04-05 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a] pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
PT3800189T (pt) 2016-05-18 2023-07-27 Array Biopharma Inc Preparação de (s)-n-(5-((r)-2-(2,5- difluoropenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroxipirrolidina-1-carboxamida
JP2019519582A (ja) 2016-06-29 2019-07-11 オリオン コーポレーション ベンゾジオキサン誘導体およびその医薬用途
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN110177581B (zh) * 2016-11-16 2023-01-03 通用医疗公司 髓过氧化物酶显像剂
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
US20220229072A1 (en) 2019-06-04 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
JPWO2021075477A1 (es) * 2019-10-16 2021-04-22
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20220389488A1 (en) * 2021-03-12 2022-12-08 Gt Molecular, Llc Multiplexed genotyping assays with a single probe using fluorescent amplitude tuning
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001333A1 (en) 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
WO1989001478A1 (en) 1987-08-07 1989-02-23 The Australian National University ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES
GB8719368D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
JPH0820584A (ja) 1994-07-04 1996-01-23 Takeda Chem Ind Ltd イミダゾール誘導体及びその用途
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
CN1183114C (zh) 1999-01-22 2005-01-05 麒麟麦酒株式会社 喹啉衍生物及喹唑啉衍生物
BR0015203A (pt) 1999-11-05 2002-07-16 Astrazeneca Ab Derivado de quinazolina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um composto, e, processo para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente
AR034118A1 (es) 2000-02-15 2004-02-04 Sugen Inc Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis
EP1506962B1 (en) 2000-10-20 2008-07-02 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic heterocycles
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
CA2551867C (en) 2003-12-31 2010-08-17 Schering-Plough Ltd. Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives
EP1813613B1 (en) * 2004-11-08 2012-12-19 Msd K.K. Novel fused imidazole derivative
EP1832588A4 (en) * 2004-12-28 2009-09-02 Takeda Pharmaceutical IMIDAZOLE CONDENSE DERIVATIVE AND APPLICATIONS THEREOF
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
JPWO2008016131A1 (ja) 2006-08-04 2009-12-24 武田薬品工業株式会社 縮合複素環化合物

Also Published As

Publication number Publication date
EP2049541A2 (en) 2009-04-22
BRPI0714665A2 (pt) 2012-03-13
AU2007279595A1 (en) 2008-02-07
US20100168424A1 (en) 2010-07-01
JP5238697B2 (ja) 2013-07-17
MX2009001349A (es) 2009-04-17
IL196799A0 (en) 2009-11-18
US20100273788A1 (en) 2010-10-28
CL2007002261A1 (es) 2008-05-02
US8044049B2 (en) 2011-10-25
US8034812B2 (en) 2011-10-11
WO2008016192A3 (en) 2008-05-08
CO6150183A2 (es) 2010-04-20
CA2659971A1 (en) 2008-02-07
PE20080538A1 (es) 2008-06-18
US20090137595A1 (en) 2009-05-28
CR10607A (es) 2009-03-12
AU2007279595A2 (en) 2009-03-19
WO2008016192A2 (en) 2008-02-07
JP2009545583A (ja) 2009-12-24
NO20090986L (no) 2009-05-04
KR20090047509A (ko) 2009-05-12
US8273741B2 (en) 2012-09-25
MA30651B1 (fr) 2009-08-03
TW200817409A (en) 2008-04-16
EP2049541B1 (en) 2015-09-23
US20090306374A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
AR062207A1 (es) Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer.
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PH12015500666A1 (en) Pyrazolopyrimidine jak inhibitor compounds and methods
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
EA200901608A1 (ru) Производные хинаксолина в качестве ингибиторов тирозинкиназной активности киназ janus
AR077468A1 (es) Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
RS53898B1 (en) QUINAZOLINE-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS
JP2009541223A5 (es)
CA2687265A1 (en) P70 s6 kinase inhibitors
AR073551A1 (es) Pirimidinas macrociclicas como inhibidores de proteina cinasa
AR089424A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
EA200900388A1 (ru) Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
ES2598830T3 (es) Compuestos bicíclicos o sales de los mismos para el uso en el tratamiento del cáncer
WO2015151006A1 (en) Substituted purine compounds as btk inhibitors
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
EA201892460A1 (ru) Производные аденина как ингибиторы протеинкиназ
AR075951A1 (es) Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek
EA200800920A1 (ru) Производные пиразоло[4,3-d]пиримидин-5-ила, применяемые в качестве ингибиторов фосфодиэстеразы 5 (pde5)
MX2021010131A (es) Formas sólidas de pirazinas condensadas a manera de inhibidores de syk.
WO2007149211B1 (en) Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
ATE548364T1 (de) Aminopyrazolkinasehemmer
RU2014127984A (ru) Хинолиновые производные как ингибиторы фермента pde10a
CA3126689C (en) A fused ring heteroaryl compound as an alk4/5 inhibitor

Legal Events

Date Code Title Description
FB Suspension of granting procedure